| P50 | author | Jean-Louis Vincent | Q3167023 |
| P2860 | cites work | Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis | Q24562848 |
| | Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis | Q24794551 |
| | The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine | Q24794570 |
| | Terlipressin for norepinephrine-resistant septic shock | Q43960661 |
| | Survival of patients with bacteraemia in relation to initial empirical antimicrobial treatment | Q44114320 |
| | Anemia and blood transfusion in critically ill patients. | Q44266321 |
| | Expression and function of the endothelial protein C receptor in human neutrophils | Q44417143 |
| | Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial | Q44506875 |
| | Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? | Q44752783 |
| | The last 100 years of sepsis | Q44996293 |
| | Terlipressin in catecholamine-resistant septic shock patients | Q45065789 |
| | Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model | Q45256622 |
| | Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany | Q47301773 |
| | The relationship between labour cost per patient and the size of intensive care units: a multicentre prospective study | Q47402757 |
| | High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury | Q47686610 |
| | Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia | Q47797708 |
| | Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom | Q48806120 |
| | Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. | Q50738804 |
| | Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. | Q51683065 |
| | Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. | Q51723077 |
| | Intra-observer variability in APACHE II scoring. | Q52935608 |
| | The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. | Q54087056 |
| | Sepsis in European intensive care units: results of the SOAP study. | Q54471944 |
| | Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. | Q54525540 |
| | Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia | Q55966607 |
| | The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine | Q24794639 |
| | Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients | Q24803954 |
| | Clinical review: Vasopressin and terlipressin in septic shock patients | Q24811923 |
| | Early goal-directed therapy in the treatment of severe sepsis and septic shock | Q27860596 |
| | Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care | Q27860820 |
| | Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network | Q27861021 |
| | The epidemiology of sepsis in the United States from 1979 through 2000 | Q29547760 |
| | Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 |
| | Intensive insulin therapy in critically ill patients | Q29618795 |
| | The pathophysiology and treatment of sepsis | Q29619103 |
| | A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group | Q29620037 |
| | Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia | Q30580297 |
| | Interobserver variability in data collection of the APACHE II score in teaching and community hospitals | Q30582099 |
| | Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden | Q31003628 |
| | Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock | Q33195919 |
| | Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock | Q34145159 |
| | Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock | Q34314380 |
| | Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose | Q34331612 |
| | The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series | Q34340908 |
| | Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death | Q34455153 |
| | Intensive insulin therapy in the medical ICU. | Q34490623 |
| | Fluid challenge revisited | Q34504724 |
| | Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 |
| | Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis | Q34683003 |
| | Has the mortality of septic shock changed with time | Q34756226 |
| | Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis | Q34999600 |
| | Clinical spectrum of mediastinal cysts | Q35174648 |
| | Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update | Q35877109 |
| | Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome | Q35948847 |
| | Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. | Q36073243 |
| | Give your patient a fast hug (at least) once a day. | Q36155146 |
| | Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition | Q36259598 |
| | New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). | Q36259602 |
| | A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock | Q40793728 |
| | Activated protein C: do more survive? | Q43571549 |
| | Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis | Q43606634 |
| | Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock | Q43617591 |
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| P304 | page(s) | 2037-2045 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Management of sepsis in the critically ill patient: key aspects | |
| P478 | volume | 7 | |